News

Satera™ Ablation System demonstrates success as a frontline treatment of heart failure Axon Therapies, a Coridea portfolio company focused on addressing one of the root causes of heart failure, announced positive interim results from their...

Avail has designed the only end-to-end system that helps surgical teams in operating rooms collaborate with remote medical experts for live procedures and clinical training Avail Medsystems, the medical technology company pioneering...

• Expansion of Axol Bioscience’s service offering for pre-clinical drug discovery • New services combine the Company’s iPSC-derived human cells and electrophysiological expertise with Axion Biosystems’ Maestro Pro MEA platform Axol...

Galaxy Medical, a developer of Pulsed Electric Field (PEF) technology for the treatment of cardiac arrhythmias, announced that the first patients in the ECLIPSE-AF study were successfully treated with the proprietary Centauri™ System by Dr....

The benefits of a more complete revascularization with Impella heart pumps in high-risk percutaneous coronary intervention (PCI) patients and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic...

Visionary leaders with proven experience commercializing technologies around the globe bring strategic insight to the company's board of directors to accelerate growth and innovation Cardiologs, a global leader in artificial intelligence...

UK Multicenter Trial to Recruit 177 Patients in Up to 15 Centers RHYTHM AI Ltd, a UK company focused on the treatment of atrial fibrillation (AF), announced that it has received approval from the UK Medicines and Healthcare Products...

Atrility Medical announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the AtriAmp™ Device. The AtriAmp facilitates more efficient monitoring and treatment of atrial arrhythmias, a common side effect of many heart surgeries....

The CARTO® 3 System and THERMOCOOL SMARTTOUCH® SF Catheter allow for a patient-tailored ablation approach, resulting in high long-term effectiveness in persistent atrial fibrillation patients* Johnson & Johnson Medical Devices...

Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Bristol Myers Squibb and MyoKardia, Inc. announced a definitive merger agreement...